The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...
NEW YORK – Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on ...
NEW YORK – Oak Hill Bio on Monday said it plans to go public through a merger with Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC), and raise funds to develop ...
Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...
The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...
It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...
Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval for AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug ...
After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...
The approval was based on the Phase III SERENA-6 trial that used ctDNA testing to detect ESR1 resistance mutations and inform treatment switching.
A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.
The firm reported that two Phase III trials of Redemplo met their primary endpoints of lowering patients' triglyceride levels.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results